Avanza Fonder AB Has $16.98 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Avanza Fonder AB increased its holdings in Boston Scientific Corporation by 8.0% during Q2, owning 158,093 shares valued at approximately $16.98 million.
• Boston Scientific reported $0.75 EPS for its latest quarter, exceeding estimates, with revenues of $5.06 billion, a 22.8% increase year-over-year.
• Institutional investors own 89.07% of Boston Scientific's stock, indicating strong institutional interest in the medical equipment company.

Avanza Fonder AB raised its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,093 shares of the medical equipment provider's stock after buying an additional 11,646 shares during the quarter. Boston Scientific makes up approximately 0.5% of Avanza Fonder AB's holdings, making the stock its 29th largest holding. Avanza Fonder AB's holdings in Boston Scientific were worth $16,981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of BSX. HM Payson & Co. boosted its stake in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares during the period. Park Square Financial Group LLC raised its holdings in shares of Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares during the last quarter. HHM Wealth Advisors LLC boosted its position in shares of Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after buying an additional 103 shares during the period. Rise Advisors LLC grew its holdings in Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock worth $85,000 after buying an additional 103 shares in the last quarter. Finally, Forum Financial Management LP grew its holdings in Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after buying an additional 112 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. UBS Group lifted their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $118.17.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 0.5%

Boston Scientific stock traded up $0.50 during midday trading on Tuesday, reaching $97.53. The stock had a trading volume of 9,258,867 shares, compared to its average volume of 7,728,375. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market cap of $144.51 billion, a price-to-earnings ratio of 58.04, a PEG ratio of 2.36 and a beta of 0.65. The firm's fifty day simple moving average is $104.25 and its two-hundred day simple moving average is $102.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.